Naturalendo Tech’s EstroG-100® Featured in SupplySide Supplement Journal Special Edition, Strengthening Its Presence in the Global Women’s Health Market
Naturalendo Tech’s women’s health ingredient EstroG-100® (combined extract of Cynanchum wilfordii, Phlomis umbrosa, and Angelica gigas) has been featured as a key women’s health ingredient in the May 2026 Product Development Guide of SupplySide Supplement Journal, further strengthening its presence in the global market. SupplySide Supplement Journal is a specialized B2B nutraceutical industry media platform operated by Informa Markets, the organizer of SupplySide Global, one of the world’s leading nutraceutical trade events. The publication recently emerged following the integration and rebranding of Natural Products Insider (NPI), a long-established North American nutraceutical industry media outlet, into the broader SupplySide media portfolio. Today, it serves as a major industry resource for ingredient suppliers, brand owners, product developers, and distribution professionals seeking insights into market trends and emerging ingredient innovations. The May 2026 issue was published as a special menopause-focused edition under the theme, “The Menopause Moment: Supporting Women Through Life’s Longest Transition.” According to industry observers, the women’s health market is rapidly evolving beyond symptom management toward broader Healthy Aging and Longevity strategies, with hormonal balance and perimenopause support emerging as major focus areas within the global nutraceutical industry. Particularly in North America, consumer demand is increasing for proactive support during the perimenopause stage rather than only after menopause, driving growing interest in clinically substantiated women’s health ingredients. The guide also highlighted the expanding global menopause market. According to the publication, the global menopause market is projected to reach approximately USD 24.4 billion by 2030, with dietary supplements accounting for more than 94% of menopause-related product sales worldwide. In addition, the U.S. menopause supplement market was reported to have reached approximately USD 741 million in 2025 and is expected to continue growing in the coming years. Industry experts increasingly view hormone-balancing Healthy Aging solutions as one of the next major growth categories in women’s health, creating stronger demand for ingredients supported by clinical evidence, safety data, and regulatory recognition. Within the special issue’s Q&A section, EstroG-100® was introduced as a non-hormonal women’s health ingredient. The publication highlighted its differentiated positioning as a women’s health solution that does not exhibit estrogen receptor-binding activity while offering support across multiple menopause-related concerns. These include hot flashes, sleep disturbances, stress, mood-related symptoms, and joint discomfort. The article also referenced emerging clinical findings associated with EstroG-100®, including research related to serotonin-mediated mood and sleep support, osteocalcin-related bone health mechanisms, and improvements in specific domains of the Female Sexual Function Index (FSFI). These findings are expected to be reported in upcoming scientific publications. The ingredient was also positioned as a proactive management solution that may be used not only after menopause but also during the perimenopause transition stage. EstroG-100® has established a growing body of clinical evidence through human studies conducted across multiple countries, including South Korea, the United States, India, and Iran. The article further highlighted the ingredient’s regulatory recognition, including U.S. FDA New Dietary Ingredient (NDI), Health Canada Natural Product Number (NPN), European Union Novel Food authorization, India FSSAI approval, and individual functional ingredient recognition from Korea’s Ministry of Food and Drug Safety (MFDS). Industry stakeholders increasingly recognize EstroG-100® as a differentiated botanical women’s health ingredient that combines a non-hormonal approach with clinical substantiation, safety data, and broad international regulatory acceptance. Commercial adoption of EstroG-100® has also continued to expand globally. Various menopause and perimenopause-focused products have been launched in North America, while women’s health brands, educational platforms, and industry media channels continue to feature EstroG-100® as a notable ingredient within the women’s health category. In addition, EstroG-100® has recently been featured in the menopause-focused publication Nourishing Menopause as a notable menopause ingredient, further expanding its visibility within the women’s health sector. “The women’s health market is rapidly evolving beyond symptom management toward Healthy Aging and Longevity,” said a representative of Naturalendo Tech. “Through continued exposure across global industry media, professional educational content, and strategic brand collaborations, we aim to further strengthen EstroG-100®’s position as a premium women’s health ingredient worldwide.” 정현식 기자supplement presence health ingredients health market perimenopause support
2026.05.28. 23:18
